Literature DB >> 21179637

Aripiprazole augmentation of combination escitalopram and sertraline in the treatment of refractory obsessive-compulsive disorder.

Adam Keller Ashton1.   

Abstract

Entities:  

Year:  2005        PMID： 21179637      PMCID： PMC3004724     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN： 1550-5952


× No keyword cloud information.
  6 in total

1.  Olanzapine augmentation for trichotillomania.

Authors:  A K Ashton
Journal:  Am J Psychiatry       Date:  2001-11       Impact factor: 18.112

2.  Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study.

Authors:  M Atmaca; M Kuloglu; E Tezcan; O Gecici
Journal:  Int Clin Psychopharmacol       Date:  2002-05       Impact factor: 1.659

3.  A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.

Authors:  C J McDougle; C N Epperson; G H Pelton; S Wasylink; L H Price
Journal:  Arch Gen Psychiatry       Date:  2000-08

4.  Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.

Authors:  E L Weiss; M N Potenza; C J McDougle; C N Epperson
Journal:  J Clin Psychiatry       Date:  1999-08       Impact factor: 4.384

5.  Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.

Authors:  Alexander Bystritsky; Deborah L Ackerman; Richard M Rosen; Tanya Vapnik; Eda Gorbis; Karron M Maidment; Sanjaya Saxena
Journal:  J Clin Psychiatry       Date:  2004-04       Impact factor: 4.384

Review 6.  The pharmacotherapy of obsessive-compulsive disorder.

Authors:  C J McDougle; W K Goodman; L H Price
Journal:  Pharmacopsychiatry       Date:  1993-05       Impact factor: 5.788
  6 in total
  1 in total

Review 1.  Critical Review of the Use of Second-Generation Antipsychotics in Obsessive-Compulsive and Related Disorders.

Authors:  Dongmi Kim; Nicole L Ryba; Julie Kalabalik; Ligia Westrich
Journal:  Drugs R D       Date:  2018-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.